FDA Peptide Rules 2026: What the New HHS Policy Means for Lifters

Written by Dr. Andrii Kaleniuk. Updated November 9, 2026.

As of November 2026, FDA peptide rules have loosened for six peptides, but nothing has been approved: a draft HHS policy published on October 30, 2026 says federal regulators will not take action against licensed pharmacies that compound BPC-157, TB-500, KPV, MOTS-c, epitalon and semax under a prescription, if they meet strict conditions. "Compounding" means a pharmacy mixing a drug for an individual patient. The policy is "enforcement discretion," a promise not to enforce for now, not FDA approval, and HHS says it may revisit it. Peptides lifters often ask about, such as CJC-1295, ipamorelin and DSIP, are not covered. "Research use only" sellers remain a target of FDA warning letters, and for tested athletes nothing has changed: BPC-157, TB-500, CJC-1295 and ipamorelin are still banned by the World Anti-Doping Agency (WADA). This guide walks through the timeline from 2023 to today, what the policy allows, how to comment before the November 13 deadline, and what comes next. It does not cover dosing or where to get peptides.

The short version: FDA restricted many popular peptides in 2023, removed a group of them from its restricted list in April 2026, an FDA advisory panel voted in July to allow most of that group, and HHS issued a draft policy in October that lets pharmacies compound six of them while a permanent rule is written. The table below lists the key dates.

Two lists decide which raw ingredients, called bulk drug substances, a pharmacy may use. The 503A bulks list, set up by a 2019 FDA final rule, names ingredients that traditional state-licensed pharmacies (known as 503A pharmacies) can compound with even though they are not part of an approved drug. A separate group of larger facilities, called 503B outsourcing facilities, has its own rules. While FDA reviews nominated ingredients, it sorts them into categories. Category 2 is the informal "do not compound" group: substances FDA says may present significant safety risks. A pharmacy that compounds a Category 2 substance risks FDA action.

FDA's Category 2 page, current as of April 22, 2026, still lists GHRP-2, GHRP-6 and ipamorelin acetate (for 503B) and kisspeptin-10 (for 503A), each added on September 29, 2023. The same page has a separate table of withdrawn nominations that includes BPC-157, CJC-1295, ipamorelin, TB-500, AOD-9604, melanotan II and others. For the background on BPC-157 itself, see what BPC-157 is.

On April 15, 2026, FDA said it would remove 12 substances from Category 2 within seven days, because the people who nominated them had withdrawn their nominations. The 12 were BPC-157, LL-37, dihexa, emideltide (DSIP), epitalon, GHK-Cu (injectable), KPV, PEG-MGF, melanotan II, MOTS-c, semax and TB-500.

This was widely misread as legalization. It was not. Law firms reviewing the announcement noted that removal from Category 2 does not make a substance eligible for compounding; it only moves it out of the "significant safety risk" group while FDA reviews it. It also did not touch ipamorelin acetate, GHRP-2 or GHRP-6, which remain on Category 2. Our page on whether BPC-157 is legal covers how this applied to BPC-157 specifically.

FDA's Pharmacy Compounding Advisory Committee (PCAC), a panel of outside experts, met on July 23 and 24, 2026, to consider seven peptides for the 503A bulks list. It voted in favor of six and against one. FDA's own staff had recommended against adding all seven. PCAC votes are advisory: FDA does not have to follow them.

The close margins matter. Several panel members voted no, and the staff review raised safety and evidence concerns. Human data on these peptides is limited, a point covered in our guides to BPC-157 side effects and whether BPC-157 causes cancer. A second PCAC meeting is expected before the end of February 2027 for GHK-Cu, LL-37, dihexa, melanotan II and PEG-MGF, but no date has been set.

On October 28, 2026, HHS announced a draft enforcement discretion policy. It was signed by Secretary Kennedy for the Office of the Secretary, not by FDA, and published in the Federal Register on October 30, 2026 (91 FR 68526, document 2026-22192). It stays in force until a final rule settles each peptide.

The policy covers the six peptides the PCAC backed. It applies to compounding by state-licensed 503A pharmacies, federal facilities and physicians. 503B outsourcing facilities are not covered. It sets 10 conditions, including ingredients from FDA-registered suppliers with certificates of analysis, a single active ingredient only, reporting of side effects to FDA's MedWatch system, the label line "This is a compounded drug product. Not for resale." and FDA-cleared syringes. Each peptide is limited to specific routes, listed in the table below.

Also excluded: intravenous (IV) use of any peptide, injectable KPV and semax, and combination products such as BPC-157 with TB-500, the pairing often called the Wolverine stack. Enforcement discretion is not FDA approval, and HHS says it may revisit the policy. A citizen petition opposing it was filed by the Partnership for Safe Medicines on October 23, 2026 (docket FDA-2026-P-13366).

Anyone can comment on the HHS policy until November 13, 2026. Comments on Federal Register documents are submitted through regulations.gov. Search for the document number, 2026-22192, or the citation 91 FR 68526, and check the notice itself for the exact docket ID before you submit, since we could not confirm it independently. Comments carry more weight when they are specific: say which peptide and which condition you are commenting on, and explain why. If you are reading this after November 13, the comment period has closed, and the next step is a final rule.

Many peptides are sold online labeled "research use only" (RUO) or "not for human consumption." FDA has made clear that this label is not a legal shield. In a March 31, 2026 warning letter about retatrutide, tirzepatide and bacteriostatic water, FDA said the RUO label "does not control." It judged the products' intended use from the seller's website claims, under a regulation (21 CFR 201.128) that lets FDA look at how a product is promoted. On that basis it treated the products as unapproved new drugs.

On August 24, 2026, FDA sent five more letters covering semaglutide, tirzepatide, retatrutide, tesamorelin, SS-31, PT-141, survodutide and mazdutide. FDA cited dosing calculators and bundled bacteriostatic water as evidence that the products were meant for people. Public Citizen counted 14 warning letters to retatrutide sellers between December 2024 and June 2026. Retatrutide is still an investigational drug; Lilly reported Phase 3 obesity results on May 21, 2026, as discussed in our retatrutide for bodybuilding article.

The HHS policy does not change any of this. It covers prescriptions compounded by licensed pharmacies under its conditions, not RUO products.

No. The HHS policy has no effect on anti-doping rules. Under the 2026 WADA Prohibited List, in effect since January 1, 2026, BPC-157 is named in section S0 (non-approved substances), which is banned at all times, in and out of competition. Section S2 covers GHRH analogues such as CJC-1295, sermorelin and tesamorelin; growth hormone secretagogues and GHRPs such as ipamorelin, GHRP-2 and GHRP-6; and thymosin-beta-4 and its derivatives, such as TB-500.

The 2027 List was approved on September 10, 2026, and takes effect January 1, 2027. It adds S0 examples and clarifications, and GLP-1 drugs remain not prohibited. Peptides not named on the list, such as KPV or MOTS-c, are not automatically allowed: S0 is a catch-all for substances without government approval for human use, so ask your anti-doping organization before assuming anything. For background on the two best-known recovery peptides, see what TB-500 is and what ipamorelin is.

Louisiana is the clearest example. Senate Bill 253, signed as Act 374 on May 22, 2026, took effect on August 1, 2026. It bars state licensing boards from disciplining prescribers and pharmacists who provide compounded peptides, as long as they follow federal rules and USP compounding standards. It does not override federal law or create a right to obtain peptides. Other states have proposed bills, but we could not confirm their final status, so they are left out here.

As of November 2026, a licensed prescriber can write a prescription for one of the six covered peptides, and a 503A pharmacy can compound it for that patient, if the pharmacy meets all 10 conditions and uses a covered route. Peptides outside the policy, including CJC-1295 and ipamorelin, are not covered, and ipamorelin acetate remains on Category 2. Approved GLP-1 drugs such as tirzepatide and semaglutide are no longer in shortage, and the shortage-era wind-down periods for compounders ended in 2025. Our article on CJC-1295 and ipamorelin side effects explains why these two remain a concern.

What comes next: FDA is expected to write a formal rule on the six peptides, which sources say will run into 2027, and a second PCAC review is expected by the end of February 2027.

FDA peptide rules in 2026 have shifted, but less than headlines suggest. Six peptides can now be compounded by licensed pharmacies under a temporary, conditional HHS policy that is not FDA approval and can be revoked. CJC-1295, ipamorelin, DSIP and peptide combinations are still left out, research use only products are still treated as unapproved drugs, and WADA bans remain unchanged for tested lifters. Watch for the outcome of the comment period, the second PCAC meeting and the final rule in 2027.

This article summarizes U.S. regulatory and anti-doping information for general purposes only and is not legal or medical advice. Rules are changing quickly; check the primary sources above for the latest status.